Soquelitinib Shows Promise Amid Loss | Business and Finance News

Corvus Pharmaceuticals’ Q2 earnings reveal soaring R&D costs and a bigger loss—but the future looks brighter with Soquelitinib, their breakthrough drug showing promise across multiple autoimmune diseases. Despite a $18M net loss, they’ve got $215M in cash to fund operations until Q2 2028. Soquelitinib’s Phase III lymphoma trial is on track, while early data in atopic dermatitis hints at lasting remission—possibly resetting the immune system. Safety remains clean, and trials are expanding into asthma, hidradenitis suppurativa, and China via Angel Pharmaceuticals, with key data expected by late 2024 and early 2027. This could redefine treatment for chronic inflammatory conditions. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/7c8541b1671754d3